Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sgn-b7h4v
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SGN-B7H4V (felmetatug vedotin) is a novel, investigational antibody-drug conjugate (ADC) targeting B7-H4, an immune checkpoint ligand overexpressed in various solid tumors such as breast, ovarian, and endometrial cancers. The ADC consists of a human monoclonal antibody directed against B7-H4 conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine citrulline (mc-vc) linker. Upon binding to B7-H4 on tumor cells, SGN-B7H4V is internalized and releases MMAE inside the cell, leading to direct cytotoxicity. Additionally, it mediates antibody-dependent cellular cytotoxicity and phagocytosis. Preclinical studies have shown robust antitumor activity both as monotherapy and in combination with anti-PD-1 agents. SGN-B7H4V is currently being evaluated in phase 1 clinical trials for advanced solid tumors[1][2][3][9].
- Brand names
- felmetatug vedotin
- Other names
- B7-H4 ADCB-7-H4 ADCB 7-H4 ADCvutisetamabum vedotinum
02
Targets
VTCN1 (V-set domain containing T cell activation inhibitor 1)
Beyond the preview
Go deeper on sgn-b7h4v.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sgn-b7h4v.